2 terminated, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow domagrozumab: new trials by email Literature Review of domagrozumab trials Research Report on domagrozumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy PF-06252616 - Duchenne Muscular Dystrophy | Phase 2 | Terminated | Pfizer | 59 | 2016-10-13 | 2020-11-23 |
| A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy PF-06252616, Placebo - Duchenne Muscular Dystrophy | Phase 2 | Terminated | Pfizer | 121 | 2014-11-24 | 2020-12-07 |
| A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects PF-06252616, Placebo, PF-06252161 - Healthy | Phase 1 | Completed | Pfizer | 86 | 2012-06-01 | 2014-09-25 |
Muscular Dystrophy, Duchenne (2)
Pfizer (3)
United States (3) · Canada (2) · Italy (2) · Japan (2) · United Kingdom (2) · Australia (1) · Bulgaria (1) · Poland (1)
PMID 32522498, PMID 36104012, PMID 34155911, PMID 34533053, PMID 35396602, PMID 35998119, PMID 36335191, PMID 39713935
2014 (1), 2016 (1)